Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Completed · Phase 1 · NCT06091943
Conditions: Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $6,988
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab IV (drug), Tislelizumab SC (drug), Histology-Based Chemotherapy Doublet (drug)
- Dates
- Started 2023-11-16; completion 2026-08-04
- Results posted
- Not yet
This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung cancer (NSCLC). This clinical study will be divided into 2 parts: dose/injection site exploration (Part 1) and dose expansion (Part 2).
From ClinicalTrials.gov, last updated 2026-08-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene USA, Inc. reported $6,988 in research payments for this study in 2025 (1 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Comprehensive Hematology Oncology $6,988
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.